Sugi Predict

Sugi Predict / Compounds / SCHEMBL29367804

SCHEMBL29367804

SCHEMBL29367804

CCOC(=O)N1c2ccccc2C=CC1OCC

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 4/20 1.00
▸ LMNA P02545 2/20 1.00
▸ MEN1 O00255 2/20 0.45
▸ KMT2A Q03164 2/20 0.45
▸ P2RX4 Q99571 6/20 0.42
▸ BCHE P06276 1/20 0.41
▸ ALDH1A1 P00352 4/20 0.41
▸ MAPK1 P28482 2/20 0.41
▸ TSHR P16473 2/20 0.41
▸ NPSR1 Q6W5P4 2/20 0.41
▸ CYP3A4 P08684 1/20 0.41
▸ CYP2C9 P11712 1/20 0.41
▸ CYP2C19 P33261 1/20 0.41
▸ GAA P10253 1/20 0.41
▸ P2RX1 P51575 3/20 0.38
▸ P2RX3 P56373 3/20 0.38
▸ P2RX7 Q99572 2/20 0.38
▸ PTBP1 P26599 1/20 0.38
▸ MAPT P10636 1/20 0.37
▸ PKM P14618 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL338 1.00 SMN1; SMN2 (1.00) SMN1; SMN2LMNAMEN1KMT2AP2RX4
SCHEMBL367474 1.00 SMN1; SMN2 (1.00) SMN1; SMN2LMNAMEN1KMT2AP2RX4
SCHEMBL23705539 1.00 SMN1; SMN2 (1.00) SMN1; SMN2LMNAMEN1KMT2AP2RX4
Carbimide SCHEMBL10800076 0.95 SMN1; SMN2 (0.90) SMN1; SMN2LMNAMEN1KMT2AP2RX4
1,2-Dichloroethane SCHEMBL28697158 0.95 SMN1; SMN2 (0.90) SMN1; SMN2LMNAMEN1KMT2AP2RX4
SCHEMBL8608444 0.93 SMN1; SMN2 (0.86) SMN1; SMN2LMNAMEN1KMT2AP2RX4
Dimethylformamide SCHEMBL7714545 0.92 SMN1; SMN2 (0.84) SMN1; SMN2LMNAMEN1KMT2AP2RX4
SCHEMBL8063974 0.91 SMN1; SMN2 (0.82) SMN1; SMN2LMNAMEN1KMT2AP2RX4
SCHEMBL8608446 0.91 SMN1; SMN2 (0.82) SMN1; SMN2LMNAMEN1KMT2AP2RX4
SCHEMBL9188247 0.90 SMN1; SMN2 (0.82) SMN1; SMN2LMNAMEN1KMT2AP2RX4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1178 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-122070936-A Nanometer material based on supermolecule polypeptide-drug coupling prodrug, and preparation method and application thereof 中国医学科学院生物医学工程研究所 2026-05-22 — — CN claimed
CN-116249536-B Batch production method of sodium taurodeoxycholate 沙裴隆有限公司 2026-05-19 — — CN claimed
CN-122036842-A Cathepsin B-sensitive fatty acid-irinotecan prodrug and albumin nanoparticle thereof, and preparation method and application thereof 沈阳药科大学 2026-05-15 — — CN claimed
CN-122036845-A Cathepsin B-sensitive fatty acid-doxorubicin prodrug, albumin nanoparticle thereof, and preparation method and application thereof 沈阳药科大学 2026-05-15 — — CN claimed
EP-4720072-A2 RAS INHIBITORS Revolution Medicines, Inc. (US) 2026-04-08 — — EP claimed
US-20260078133-A1 RAS INHIBITORS Revolution Medicines, Inc. 2026-03-19 — — US claimed
US-20260078124-A1 METHODS OF PREPARING ERGOLINE ANALOGS UNIV CALIFORNIA (US) 2026-03-19 — — US claimed
EP-4688790-A1 MACROCYCLIC RAS INHIBITORS Revolution Medicines, Inc. (US) 2026-02-11 — — EP claimed
US-20260028353-A1 MACROCYCLIC RAS INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION, AS ADMINISTRATIVE AGENT 2026-01-29 — — US claimed
US-12473265-B2 Methods for preparing PSMA conjugates ENDOCYTE, INC. (US) 2025-11-18 — — US claimed
US-20220220085-A1 METHODS FOR PREPARING PSMA CONJUGATES ENDOCYTE, INC. 2022-07-14 — — US claimed
CN-114539536-A Preparation method and application of perfluoropolyether surfactant containing amide bonds 华南师范大学 2022-05-27 — — CN claimed
CN-114437151-A Albumin-binding camptothecin derivative prodrug and preparation method and application thereof 华东师范大学 2022-05-06 — — CN claimed
CN-114349812-A Compound for solidifying ether organic waste liquid and preparation method thereof 中北大学 2022-04-15 — — CN claimed
WO-2022064454-A1 A PROCESS FOR THE SYNTHESIS OF ANTHRANILIC ACID/AMIDE COMPOUNDS AND INTERMEDIATES THEREOF PI INDUSTRIES LTD. (IN) 2022-03-31 — — WO claimed
EP-3972627-A1 METHODS FOR PREPARING PSMA CONJUGATES Endocyte, Inc. (US) 2022-03-30 — — EP claimed
CN-114213669-A Polyoxometallate giant surfactant and preparation method and application thereof 东华大学 2022-03-22 — — CN claimed
CN-114195838-A Bimolecular galactose derivative-based hydrogel and preparation method thereof 中北大学 2022-03-18 — — CN claimed
CN-114096264-A Process for preparing PSMA conjugates 因多塞特股份有限公司 2022-02-25 — — CN claimed
CN-110790810-B Rocuronium bromide intermediate and preparation method of rocuronium bromide 重庆仁泽医药科技有限公司 2022-01-28 — — CN claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260078133-A1 RAS INHIBITORS KRAS, NRAS, HRAS SMN1; SMN2 4034/4885LMNA 2548/4885MEN1 1379/4885
US-20260028353-A1 MACROCYCLIC RAS INHIBITORS KRAS, NRAS, HRAS SMN1; SMN2 3943/4885LMNA 2273/4885MEN1 1399/4885
US-20220220085-A1 METHODS FOR PREPARING PSMA CONJUGATES FOLH1, PSMA6, PSMA1 SMN1; SMN2 1186/4885LMNA 2413/4885MEN1 554/4885
US-20260078124-A1 METHODS OF PREPARING ERGOLINE ANALOGS HTR1A, HTR2A, HTR7 SMN1; SMN2 641/4885LMNA 1083/4885MEN1 1839/4885
US-12473265-B2 Methods for preparing PSMA conjugates FOLH1, PSMA6, PSMA1 SMN1; SMN2 1186/4885LMNA 2413/4885MEN1 554/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.